Next Article in Journal
A New Folding Kinetic Mechanism for Human Transthyretin and the Influence of the Amyloidogenic V30M Mutation
Next Article in Special Issue
Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine
Previous Article in Journal
A Long Noncoding RNA ZEB1-AS1 Promotes Tumorigenesis and Predicts Poor Prognosis in Glioma
Previous Article in Special Issue
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type

Institut Jean Godinot, Unicancer, 1 rue du Général Koenig, F-51726 Reims, France
Université Reims-Champagne-Ardenne, DERM-I-C, EA7319, 51 rue Cognacq-Jay, F-51095 Reims, France
Centre Hospitalo-Universitaire Henri Mondor, Service de Radiothérapie, 51 Avenue du Maréchal de Lattre de Tassigny, F-94010 Créteil, France
Institut National de la Santé et de la Recherche Médicale (INSERM) U976, Hôpital Saint Louis, F-75010 Paris, France
Université Paris Diderot, Sorbonne Paris Cité, Laboratoire Immunologie Dermatologie & Oncologie, UMR-S 976, F-75475 Paris, France
OREGA Biotech, 69130 Ecully, France
Authors to whom correspondence should be addressed.
Academic Editor: Anthony Lemarie
Int. J. Mol. Sci. 2016, 17(9), 1433;
Received: 1 July 2016 / Revised: 10 August 2016 / Accepted: 24 August 2016 / Published: 30 August 2016
The inflammatory process contributes to immune tolerance as well as to tumor progression and metastasis. By releasing extracellular signals, cancerous cells constantly shape their surrounding microenvironment through their interactions with infiltrating immune cells, stromal cells and components of extracellular matrix. Recently, the pro-inflammatory interleukin 17 (IL-17)-producing T helper lymphocytes, the Th17 cells, and the IL-17/IL-17 receptor (IL-17R) axis gained special attention. The IL-17 family comprises at least six members, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F. Secreted as disulfide-linked homo- or heterodimers, the IL-17 bind to the IL-17R, a type I cell surface receptor, of which there are five variants, IL-17RA to IL-17RE. This review focuses on the current advances identifying the promoting role of IL-17 in carcinogenesis, tumor metastasis and resistance to chemotherapy of diverse solid cancers. While underscoring the IL-17/IL-17R axis as promising immunotherapeutic target in the context of cancer managing, this knowledge calls upon further in vitro and in vivo studies that would allow the development and implementation of novel strategies to combat tumors. View Full-Text
Keywords: interleukin 17 (IL-17); cancer; tumor microenvironment; immunotherapy interleukin 17 (IL-17); cancer; tumor microenvironment; immunotherapy
Show Figures

Graphical abstract

MDPI and ACS Style

Fabre, J.; Giustiniani, J.; Garbar, C.; Antonicelli, F.; Merrouche, Y.; Bensussan, A.; Bagot, M.; Al-Dacak, R. Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. Int. J. Mol. Sci. 2016, 17, 1433.

AMA Style

Fabre J, Giustiniani J, Garbar C, Antonicelli F, Merrouche Y, Bensussan A, Bagot M, Al-Dacak R. Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type. International Journal of Molecular Sciences. 2016; 17(9):1433.

Chicago/Turabian Style

Fabre, Joseph, Jerome Giustiniani, Christian Garbar, Frank Antonicelli, Yacine Merrouche, Armand Bensussan, Martine Bagot, and Reem Al-Dacak. 2016. "Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type" International Journal of Molecular Sciences 17, no. 9: 1433.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop